{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:41:14Z","timestamp":1787733674065,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01638-7","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:13:37Z","timestamp":1743743617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed\/refractory T-cell acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"25","author":[{"given":"Fangfei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingshuo","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-5599","authenticated-orcid":false,"given":"Kuangguo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"31","key":"1638_CR1","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","volume":"23","author":"HG Einsiedel","year":"2005","unstructured":"Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-M\u00fcnster Group 87. J Clin Oncol. 2005;23(31):7942\u201350.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1638_CR2","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009;27(20):3363\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1638_CR3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109(3):944\u201350.","journal-title":"Blood"},{"issue":"10","key":"1638_CR4","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341.","journal-title":"Blood"},{"issue":"8","key":"1638_CR5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00277-023-05286-3","volume":"102","author":"YH Huang","year":"2023","unstructured":"Huang YH, Wan CL, Dai HP, Xue SL. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia\/lymphoma. Ann Hematol. 2023;102(8):2001\u201313.","journal-title":"Ann Hematol"},{"issue":"6","key":"1638_CR6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","volume":"109","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Vinanica N, Wong DMH, Campana D. Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia. Haematologica. 2024;109(6):1677\u201388.","journal-title":"Haematologica"},{"issue":"25","key":"1638_CR7","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738\u201347.","journal-title":"Blood"},{"issue":"7","key":"1638_CR8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"1638_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333.","journal-title":"Ann Oncol"},{"issue":"2","key":"1638_CR10","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u201371.","journal-title":"Haematologica"},{"issue":"18","key":"1638_CR11","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.3390\/ijms231810957","volume":"23","author":"S Aumann","year":"2022","unstructured":"Aumann S, Shaulov A, Haran A, Gross Even-Zohar N, Vainstein V, Nachmias B. The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2022;23(18):10957.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1638_CR12","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/ijc.34819","volume":"154","author":"Y Walia","year":"2024","unstructured":"Walia Y, de Bock CE, Huang Y. The landscape of alterations affecting epigenetic regulators in T-cell acute lymphoblastic leukemia: Roles in leukemogenesis and therapeutic opportunities. Int J Cancer. 2024;154(9):1522\u201336.","journal-title":"Int J Cancer"},{"key":"1638_CR13","first-page":"6092646","volume":"2018","author":"LT Rahmat","year":"2018","unstructured":"Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN. Venetoclax in combination with decitabine for relapsed T-Cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant. Case Rep Hematol. 2018;2018:6092646.","journal-title":"Case Rep Hematol"},{"issue":"10","key":"1638_CR14","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/ccr3.3041","volume":"8","author":"E Zappone","year":"2020","unstructured":"Zappone E, Cencini E, Defina M, Sicuranza A, Gozzetti A, Ciofini S, et al. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep. 2020;8(10):2000\u20132.","journal-title":"Clin Case Rep"},{"issue":"7","key":"1638_CR15","doi-asserted-by":"crossref","first-page":"e991","DOI":"10.1097\/MPH.0000000000002050","volume":"43","author":"MU Baig","year":"2021","unstructured":"Baig MU, Rytting M, Roth M, Morani AC, Nunez C, Lin P, et al. Venetoclax and decitabine in pediatric refractory T-cell lymphoblastic lymphoma. J Pediatr Hematol Oncol. 2021;43(7):e991\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"1638_CR16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","volume":"14","author":"N Farhadfar","year":"2021","unstructured":"Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a case report and review of literature. Hematol Oncol Stem Cell Ther. 2021;14(3):246\u201351.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"3","key":"1638_CR17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-021-04530-y","volume":"101","author":"J Kong","year":"2022","unstructured":"Kong J, Chen N, Li M, Zhang J, Wu X, Zong L, et al. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia. Ann Hematol. 2022;101(3):697\u20139.","journal-title":"Ann Hematol"},{"issue":"13","key":"1638_CR18","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","volume":"62","author":"CL Wan","year":"2021","unstructured":"Wan CL, Zou JY, Qiao M, Yin J, Shen XD, Qiu QC, et al. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leuk Lymphoma. 2021;62(13):3300\u20133.","journal-title":"Leuk Lymphoma"},{"key":"1638_CR19","first-page":"1501","volume":"142","author":"H-Y Cao","year":"2023","unstructured":"Cao H-Y, Chen L-L, Wan C-L, Hu X-H, Wu B, Yang L, et al. Venetoclax combined with azacitidine was effective and safe for relapsed\/refractory T-Cell acute lymphoblastic leukemia\/ lymphoblastic lymphoma: preliminary results of a Phase 2. Multicenter Trial Blood. 2023;142:1501.","journal-title":"Multicenter Trial Blood"},{"key":"1638_CR20","doi-asserted-by":"crossref","first-page":"1358161","DOI":"10.3389\/fmed.2024.1358161","volume":"11","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Ji L, Jin X, Wu H, He M, Shen F, et al. Case report: Treatment of two cases of recurrent\/refractory early T-cell precursor acute lymphoblastic leukemia with venetoclax combined with the CAG regimen. Front Med (Lausanne). 2024;11:1358161.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1638_CR21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/1078-0432.CCR-23-2159","volume":"30","author":"A Pinton","year":"2024","unstructured":"Pinton A, Courtois L, Doublet C, Cabannes-Hamy A, Andrieu G, Smith C, et al. PHF6-altered T-ALL harbor epigenetic repressive switch at bivalent promoters and respond to 5-azacitidine and venetoclax. Clin Cancer Res. 2024;30(1):94\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1638_CR22","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.medj.2024.07.018","volume":"5","author":"S Suo","year":"2024","unstructured":"Suo S, Sun S, Nguyen LXT, Qian J, Li F, Zhao D, et al. Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed. Med. 2024;5(12):1510-24.e4.","journal-title":"Med"},{"issue":"15","key":"1638_CR23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863\u20139.","journal-title":"Blood"},{"issue":"10","key":"1638_CR24","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41592-024-02405-4","volume":"21","author":"CF Kurz","year":"2024","unstructured":"Kurz CF, Krzywinski M, Altman N. Propensity score matching. Nat Methods. 2024;21(10):1770\u20132.","journal-title":"Nat Methods"},{"issue":"3","key":"1638_CR25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood.2024023944","volume":"144","author":"C Sarkozy","year":"2024","unstructured":"Sarkozy C, Callanan M, Thieblemont C, Ob\u00e9ric L, Burroni B, Bouabdallah K, et al. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma. Blood. 2024;144(3):262\u201371.","journal-title":"Blood"},{"issue":"10","key":"1638_CR26","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.clml.2018.07.289","volume":"18","author":"J El-Cheikh","year":"2018","unstructured":"El-Cheikh J, Moukalled NM, El Darsa H, Massoud R, Kanj SS, Mahfouz R, et al. Feasibility of the combination of venetoclax and asparaginase-based chemotherapy for adult patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(10):e441\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1638_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00127","volume":"2","author":"Y Numan","year":"2018","unstructured":"Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, et al. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2018;2:1.","journal-title":"JCO Precis Oncol"},{"key":"1638_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00172","volume":"3","author":"R La Starza","year":"2019","unstructured":"La Starza R, Camb\u00f2 B, Pierini A, Bornhauser B, Montanaro A, Bourquin JP, et al. Venetoclax and bortezomib in relapsed\/refractory early T-Cell precursor acute lymphoblastic leukemia. JCO Precis Oncol. 2019;3:1.","journal-title":"JCO Precis Oncol."},{"issue":"4","key":"1638_CR29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-Cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(4):212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"1638_CR30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","volume":"99","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li J, Jin J, Yu W. Relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen. Ann Hematol. 2020;99(2):395\u20137.","journal-title":"Ann Hematol"},{"issue":"11","key":"1638_CR31","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00277-022-04912-w","volume":"101","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Dai Y, Tang X. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed\/refractory T-cell acute lymphoblastic leukaemia. Ann Hematol. 2022;101(11):2525\u20138.","journal-title":"Ann Hematol"},{"issue":"5","key":"1638_CR32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MPH.0000000000002672","volume":"45","author":"P Borah","year":"2023","unstructured":"Borah P, Dayal N, Pathak S, Naithani R. Short-course venetoclax with standard chemotherapy is effective in early T-cell precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2023;45(5):271\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"1638_CR33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/ejh.14015","volume":"111","author":"J Canaani","year":"2023","unstructured":"Canaani J, Frisch A, Pollyea DA, Schwartz M, Aumann S, Ganzel C, et al. Venetoclax-based salvage therapy for adult patients with relapsed\/refractory acute lymphoblastic leukemia. Eur J Haematol. 2023;111(3):365\u201372.","journal-title":"Eur J Haematol"},{"issue":"8","key":"1638_CR34","first-page":"649","volume":"44","author":"JY Kong","year":"2023","unstructured":"Kong JY, Zong LH, Pu Y, Liu Y, Kong X, Li MY, et al. Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2023;44(8):649\u201353.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1638_CR35","doi-asserted-by":"crossref","first-page":"1228481","DOI":"10.3389\/fonc.2023.1228481","volume":"13","author":"W Prejzner","year":"2023","unstructured":"Prejzner W, Pieko\u015b O, Be\u0142dzi\u0144ska K, Sadowska-Klasa A, Zarzycka E, Bieniaszewska M, et al. The role of daratumumab in relapsed\/refractory CD38 positive acute leukemias-case report on three cases with a literature review. Front Oncol. 2023;13:1228481.","journal-title":"Front Oncol"},{"issue":"4","key":"1638_CR36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-023-03623-w","volume":"118","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Jiang S, Tang Y, Zhao L. Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review. Int J Hematol. 2023;118(4):483\u20138.","journal-title":"Int J Hematol"},{"issue":"5","key":"1638_CR37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jha2.991","volume":"5","author":"ND Palmisiano","year":"2024","unstructured":"Palmisiano ND, Lee JW, Claxton DF, Paietta EM, Alkhateeb H, Park J, et al. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol. EJHaem. 2024;5(5):951\u20136.","journal-title":"EJHaem"},{"issue":"8","key":"1638_CR38","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1007\/s00277-024-05775-z","volume":"103","author":"H Shi","year":"2024","unstructured":"Shi H, Yang F, Cao M, Xu T, Zheng P, Guo Y, et al. Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: Single-arm, open-label, phase I study. Ann Hematol. 2024;103(8):2993\u20133004.","journal-title":"Ann Hematol"},{"issue":"4","key":"1638_CR39","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, et al. A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv. 2024;8(4):909\u201315.","journal-title":"Blood Adv"},{"issue":"1","key":"1638_CR40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.19493","volume":"205","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhong Y, Liu L, Suo S, Zhao S, Xiao F, et al. MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: a case report. Br J Haematol. 2024;205(1):352\u20135.","journal-title":"Br J Haematol"},{"issue":"6","key":"1638_CR41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11(6):1440\u201353.","journal-title":"Cancer Discov"},{"issue":"21","key":"1638_CR42","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","volume":"144","author":"T Bhatla","year":"2024","unstructured":"Bhatla T, Hogan LE, Teachey DT, Bautista F, Moppett J, Velasco Puy\u00f3 P, et al. Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study. Blood. 2024;144(21):2237\u201347.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01638-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01638-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01638-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:55Z","timestamp":1764917335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01638-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01638-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by the Ethical Review Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Ethics approval number: TJ-IRB20230886.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"104"}}